Binimetinib treats melanoma

Binimetinib (Binimetinib) is a non-competitive and selective mitogen-activated protein kinase (MEK1/2) small molecule inhibitor. This MEK inhibitor, originally developed by Array Biopharma Inc., is being evaluated in combination with encorafenib for the treatment of metastatic cutaneous melanoma given its role as an anti-cancer therapeutic strategy. Cutaneous melanoma is an uncontrolled proliferation of melanocytes caused by genetic mutations primarily caused by UV-mediated exposure.

The drug's preclinical and clinical trial data demonstrate its efficacy against cancer, specifically melanoma withBRAF and NRAS mutations. Phase 1 and 2 data showed that the 45 mg BID dose was reasonably well tolerated in patients with BRAF-mutated metastatic melanoma, and phase 3 data showed that the combination with encorafenib doubled PFS (14.9 months) compared with vemurafenib alone (14.9 months). Given that it is only approved in combination and not as monotherapy, it is not currently a first-line treatment for metastatic melanoma. Therefore, it is important to take an individualized approach when considering which patients should be considered for this regimen compared with standard-of-care immunotherapy or vemurafenib regimens. Treating clinicians must evaluate several factors in their patient's risk-benefit analysis, including drug side effects, cost, and oncologic benefit, because durable complete responses have not been observed with bimetinib combination therapy compared with immunotherapy in this disease.

The original drug bimetinib has not yet been launched in China, and therefore is not covered by medical insurance. Bimetiniboriginal drug sold overseas, specifications15mg*84 tablets may cost more than 10,000 yuan per box (the price may fluctuate due to exchange rates), which is relatively expensive. There is currently no generic drug of Bimetinib produced and launched. For more drug information and specific prices, please consult a medical consultant.